登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JMV，2月28日，Development of epitope‐based peptide vaccine against novel Coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-01

  • Development of epitope‐based peptide vaccine against novel Coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach

    Manojit Bhattacharya Ashish Ranjan Sharma Prasanta Patra Pratik Ghosh Garima Sharma Bidhan Chandra Patra Sang‐Soo Lee Chiranjib Chakraborty

    First published:28 February 2020 https://doi.org/10.1002/jmv.25736

    ABSTRACT

    Recently, a novel Coronavirus (SARS‐COV‐2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to the SARS‐CoV and MERS‐CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS‐COV‐2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex‐(MHC) I and 3 MHC‐II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on Toll‐Like Receptor (TLR)‐5 to get binding affinity. Therefore, in order to provide a fast immunogenic profile of these epitopes we performed immunoinformatics analysis so that rapid development of vaccine might bring this disastrous situation to the end earlier.

  • 原文来源：https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25736
42浏览量
原文链接
相关报告

  • 《BioRxiv，2月27日，Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-28
    • Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2 Lin Li, Ting Sun, YuFei He, Wendong Li, Yubo Fan, Jing Zhang doi: https://doi.org/10.1101/2020.02.25.965434 Abstract The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected thousands of people with a large number of deaths across 26 countries. The sudden appearance of the virus leads to the limited existing therapies for SARS-CoV-2. Therefore, vaccines and antiviral medicines are in desperate need. This study took immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    108浏览量
    原文链接

  • 《BioRxiv，2月11日，Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-12
    • Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach Miysaa I. Abdelmageed, Abdelrahman Hamza Abdelmoneim Sr., Mujahed I. Mustafa Sr., Nafisa M. Elfadol, Naseem S. Murshed, Shaza W. Shantier, Abdelrafie M. Makhawi doi: https://doi.org/10.1101/2020.02.04.934232 Abstract Background: on the late December 2019, a new endemic has been spread across Wuhan City, China; within a few weeks, a novel coronavirus designated as 2019 novel coronavirus (2019-nCoV) was announced by the World Health Organization (WHO). In late January 2020, WHO declared the outbreak a public-health emergency of international concern due to the rapid spreading and increasing worldwide. There is no vaccine or approved treatment for this emerging infection; therefore, the objective of this paper is to design a multi epitope peptide vaccine against 2019-nCoV using immunoinformatics approach. Method: We will highlight a technique facilitating the combination of immunoinformatics approach with comparative genomic approach to determine our potential target for designing the T cell epitopes-based peptide vaccine using the envelope protein of 2019-nCoV as a target. Results: Extensive mutations, insertion and deletion were discovered with comparative sequencing in 2019-nCoV strain; in addition, 10 MHC1 and MHC2 related peptides were promising candidates for vaccine design with adequate world population coverage of 88.5% and 99.99% respectively. Conclusion: T cell epitopes-based peptide vaccine was designed for 2019-nCoV using envelope protein as an immunogenic target; nevertheless, the proposed T cell epitopes-based peptide vaccine rapidly needs to validates clinically to ensure its safety and immunogenic profile to assist on stopping this epidemic before it leads to devastating global outbreaks. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    37浏览量
    原文链接